Off-Label Drug Lowers Relapses in Multiple Sclerosis
Study paves way for rituximab to be considered for MS in some countries
Source: medpagetoday.com
Stay updated with breaking news from Anders Svenningsson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study paves way for rituximab to be considered for MS in some countries
THURSDAY, July 14, 2022 (HealthDay News) -- A drug used "off-label" for multiple sclerosis (MS) is more effective than a standard medication at preventing symptom flare-ups, a new clinical trial